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Background: Cognitive behaviour therapy (CBT) is an effective treatment for depression. However, CBT is a
complex therapy that requires highly trained and qualified practitioners, and its scalability is therefore limited by the
costs of training and employing sufficient therapists to meet demand. Behavioural activation (BA) is a psychological
treatment for depression that may be an effective alternative to CBT and, because it is simpler, might also be
delivered by less highly trained and specialised mental health workers.
Methods/Design: COBRA is a two-arm, non-inferiority, patient-level randomised controlled trial, including clinical,
economic, and process evaluations comparing CBT delivered by highly trained professional therapists to BA delivered
by junior professional or para-professional mental health workers to establish whether the clinical effectiveness of BA is
non-inferior to CBT and if BA is cost effective compared to CBT. Four hundred and forty patients with major depressive
disorder will be recruited through screening in primary care. We will analyse for non-inferiority in per-protocol and
intention-to-treat populations. Our primary outcome will be severity of depression symptoms (Patient Health
Questionnaire-9) at 12 months follow-up. Secondary outcomes will be clinically significant change and severity of
depression at 18 months, and anxiety (General Anxiety Disorder-7 questionnaire) and health-related quality of life
(Short-Form Health Survey-36) at 12 and 18 months. Our economic evaluation will take the United Kingdom National
Health Service/Personal Social Services perspective to include costs of the interventions, health and social care services
used, plus productivity losses. Cost-effectiveness will explored in terms of quality-adjusted life years using the
EuroQol-5D measure of health-related quality of life.
Discussion: The clinical and economic outcomes of this trial will provide the evidence to help policy makers, clinicians
and guideline developers decide on the merits of including BA as a first-line treatment of depression.
Trial registration: Current Controlled Trials ISRCTN27473954Background
Clinical depression is one of the most common and debili-
tating of the psychiatric disorders. It accounts for the
greatest burden of disease among all mental health prob-
lems, and is expected to become the second largest
amongst all general health problems by 2020 [1]. Lifetime* Correspondence: d.a.richards@exeter.ac.uk
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benefit payments and lost tax receipts [6].
Antidepressant medication (ADM) and cognitive behav-
iour therapy (CBT) are the two treatments with most
evidence of effectiveness; both are recommended by
the National Institute for Health and Care Excellence
(NICE) [7]. Problems with ADM include side effects,
poor patient adherence and relapse risk on ADM discon-
tinuation. Service-user organisations and policy think
tanks advocate greater availability of psychological therap-
ies, which many people prefer [8]. CBT, which is of similar
efficacy to ADM [9], has several advantages: 1) it reflects
the desire of many service users for non-pharmacological
treatment; 2) it has no physical side-effects; and 3) it
modifies the illness trajectory in that benefits continue
after the end of treatment thereby reducing rates of re-
currence [10]. However, CBT has several limitations: 1)
its complexity may make it difficult to learn to implement
in a competent fashion; 2) there is some evidence that its
efficacy is dependent upon the skill of the individual prac-
titioner; 3) patients are required to learn high-level skills;
and 4) the high costs of training and employing sufficient
therapists limits access to CBT.
As a consequence of the problems above, many people
do not receive adequate treatment and even, when treat-
ment is given, many respond only partially or not at all
[11]. For example, despite the recent UK government
initiative in England - ‘Improving Access to Psychological
Therapies’ (IAPT: http://www.iapt.nhs.uk/) - no more than
15% of people with depression will receive National
Health Service (NHS)-delivered CBT and only 50% will re-
cover [12]. It is therefore important to continue to test
promising new treatments, especially if: there are indi-
cations that such treatments reduce the risk of symp-
tom return; are applicable to a wide range of depressed
people including those with high severity; are easy to
implement in clinical practice and are therefore potentially
more accessible [13]; and are a cost-effective use of re-
sources. Indeed, in order to meet public and professional
expectations, health services require simple, equivalently
effective, easily implemented psychological treatments
for depression that can be delivered by less specialist
(albeit appropriately competent) junior or para-professional
health workers to treat many more people with depression
in a more cost-effective manner.
Behavioural activation (BA) is a psychological treat-
ment based on behavioural theory that alleviates depres-
sion by focusing directly on changing behaviour [14-16].
This theory states that depression is maintained in part
by avoidance of normal activities. As people withdraw
and disrupt their basic routines, they become isolated from
positive reinforcement opportunities in their environment.
The combination of increased negative reinforcement
with reduced positive reinforcement results in a cycleof depressed mood, decreased activity and avoidance
which maintains depression [15]. BA systematically
disrupts this cycle, initiating approach-oriented behav-
iours in the presence of negative mood, when people’s
natural tendency is to withdraw or avoid [17,18]. Al-
though CBT incorporates some behavioural elements,
these commonly focus on increasing rewarding activity
and initiating behavioural experiments to test specific
beliefs. In contrast, BA targets avoidance from a con-
textual, functional approach not found in CBT - that
is, BA focuses on understanding the function of behav-
iour and replacing it accordingly. BA also explicitly
prioritises the treatment of negatively reinforced avoidance
and rumination. Furthermore, because the BA rationale is
simpler, it should be easier to understand and operational-
ise for both patients and mental health workers than CBT,
where activity is also increased but the primary techniques
focus on changing maladaptive beliefs [19]. Moreover,
there is some evidence that CBT is less effective when
delivered by less competent therapists [9,20].
In the UK, CBT is delivered by professionally qualified
senior mental health workers (mainly clinical psychology,
nursing, occupational therapy, social work or counselling),
who have obtained a further 1 year full time post-graduate
qualification in CBT. Their training is long and expensive
and their employment grade is costly compared to junior
professionals or para-professional mental health workers
who deliver much of the routine mental health care in the
UK. The relative simplicity of BA treatment may make it
easier and cheaper to train para-professional mental health
workers in its application than CBT, the argument of ‘parsi-
mony’ first advanced by one of the early proponents of this
approach, Neil Jacobson, more than 10 years ago [15].
Limitations of previous trials
We conducted a meta-analysis of randomised controlled
trials of BA [21] where we first found a clinical effect size in
terms of a reduced depression score of −0.70 SD units from
twelve studies (n = 459; 95% CI −1.00 to −0.39; P < 0.001)
comparing behavioural treatments to controls using experi-
enced therapists. We then found twelve studies comparing
behavioural treatments with CBT (n = 476) and showed
that behavioural treatments had equivalent outcomes to
CBT (pooled SMD 0.08; 95% CI −0.14 to 0.30, P = 0.46).
Meta regression of results exploring association between
baseline severity and effect size identified a statistically
significant result in favour of BA (meta-regression b-
coefficient −0.05; 95% CI −0.10 to −0.01; P = 0.04).
However, many of the trials were of limited methodo-
logical quality, all were under-powered for comparing treat-
ments, and most did not utilise diagnostic interviews for
trial inclusion. Treatments in many cases did not conform
to modern clinical protocols for BA. Long-term outcomes
were rarely reported, with average follow-up only to 4
Rhodes et al. Trials 2014, 15:29 Page 3 of 12
http://www.trialsjournal.com/content/15/1/29months. These results have been replicated in two re-
cent Cochrane reviews of behavioural therapies [22,23]
which concluded that there was only low- to moderate-
quality evidence that behavioural therapies and other
psychological therapies were equally effective and called
for ‘Studies recruiting larger samples with improved
reporting of design and fidelity to treatment’ to ‘improve
the quality of the evidence’ [22] (page 2).
Therefore, the existing trial data are insufficient to
provide certainty that BA should be a first-line treatment
for depression and these limitations led to NICE in the
UK regarding the evidence for BA as equivocal and of in-
sufficient strength to recommend BA for first-line routine
NHS depression treatment [7]. Consequently, NICE made
a clear research recommendation “to establish whether be-
havioural activation is an effective alternative to CBT” using
a study “large enough to determine the presence or absence
of clinically important effects using a non-inferiority design”
[7] (page 256).
Pilot work preceding this trial
In order to test uncertainties around our main objec-
tives, we piloted BA in a phase II randomised controlled
trial to examine whether mental health workers without
previous specialist training in psychological therapy can
effectively treat depressed people using BA [24]. We
compared BA against usual care. Relatively junior NHS
mental health workers ('band 5' - equivalent to a basic
grade qualified mental health nurse) with no previous
formal training or experience in psychotherapy delivered
BA. These workers received 5 days training in BA and
subsequent 1-hour clinical supervision fortnightly from
a clinical nurse consultant or trained psychotherapist.
Intention-to-treat (ITT) analyses indicated a difference in
favour of BA of −15.79 (n = 47; 95% CI −24.55 to −7.02) on
depression (Beck Depression Inventory-II), an effect size
of −1.15 SD units (95% CI −0.45 to −1.85). We also found a
quality-adjusted life year (QALY) difference in favour of be-
havioural activation of 0.20 (95% CI 0.01 to 0.39, P = 0.042),
incremental cost-effectiveness ratio of £5,756 per QALY
and a 97% probability that behavioural activation is more
cost-effective at a threshold value of £20,000 [25].
Objectives
1 What is the clinical effectiveness of BA compared to
CBT for depressed adults in terms of depression
treatment response at 12 and 18 months?
2 What is the cost-effectiveness of BA compared to
CBT at 18 months?
It is hypothesised that BA is non-inferior compared to
CBT in reducing depression severity but that BA will be
less costly and thus more cost-effective than CBT.In addition, we will undertake a secondary process evalu-
ation to investigate the moderating, mediating and proced-
ural factors in BA and CBT that influence outcome.
Methods/Design
COBRA is a two-arm, non-inferiority, patient-level
randomised controlled trial, including clinical, economic
and process evaluation for people with depression. We
will test the effectiveness of a psychological intervention
for depression - BA - against CBT, the current gold
standard evidence-based psychological treatment for de-
pression. The rationale for a non-inferiority trial is that
we wish to establish whether the clinical effectiveness of
BA is not substantially inferior to CBT and to determine
if BA represents a viable first choice of treatment in the
management of depression. Accordingly, we have pow-
ered our trial on the basis of clinical non-inferiority, and
will analyse our data accordingly [26,27].
Setting and participants
We will recruit participants from the electronic case records
of primary care general practices in three UK sites: Devon,
Durham and Leeds. Eligible participants will be aged 18 and
older with DSM Major Depressive Disorder assessed by
standard clinical interview (Structured Clinical Interview for
Depression; SCID) [28]. People will be excluded if they are
alcohol or drug dependent, are currently acutely suicidal
or have made a suicide attempt in the previous 2 months,
are cognitively impaired, or have a bipolar disorder or
psychosis/psychotic symptoms. We will also exclude people
currently in receipt of psychological therapy.
Randomisation, concealment of allocation, and blinding
Participants will be allocated in a 1:1 ratio to either the
BA or CBT arms stratified according to their symptom
severity on the Patient Health Questionnaire 9 (PHQ-9)
[29] (PHQ-9 <19 versus ≥19), antidepressant use (currently
using anti-depressants or not) and recruitment site. A
computer-based system will allocate the first 20 participants
to each arm on a truly random basis. For subsequent
participants, allocation will be minimised to maximise the
likelihood of balance in stratification variables across the
two study arms. Concealment will be ensured by use of an
externally administered password-protected trial website
and retaining a stochastic element to the minimisation algo-
rithm. The computer-based allocation and website will be
setup and maintained by the accredited Peninsula Clinical
Trials Unit, independent of the trial. The participant’s details
will be sent to the relevant mental health worker to alert
them to contact this person and begin treatment.
All research measures will be applied to both groups
of participants equally. Researchers will be blind to group
allocation, which will occur after baseline assessments.
At follow-up, researchers will be instructed to maintain
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nature of their treatment and the need not to discuss
this with researchers. We will test blindness by asking
researchers to indicate at follow-up which treatment
they believe the participants received and analyse any
correlation with outcome.
Recruitment
Randomised controlled trials are vulnerable to selection
bias and threats to external validity if there are system-
atic differences in behaviour between referring clinicians.
We will minimise this potential bias by recruiting par-
ticipants through searching general practice records and
referral logs from primary care to local depression and
anxiety treatment services, rather than by direct referral
from general practitioners (GPs). We will identify suit-
able participants by examining electronic case records
for all patients in each general practice or treatment ser-
vice. The GP search will be limited to people seen by
their GPs in the previous 2 months who have been allo-
cated at least one identification code in their electronic
records. Several such codes are widely used by general
practitioners to classify patients. Practice staff or Research
Network Clinical Studies Officers will conduct searches.
The list of potentially suitable participants will be
reviewed by GPs to identify any patients whom have
known exclusion criteria. The remaining patients will
be written to by their GP practice, inviting them to
take part in the study. For patients already referred to
local psychological therapies services, we will contact
those on the waiting list. A short participant information
sheet, stamped addressed envelope and a ‘Permission for
Researcher to Contact’ form to allow a researcher to con-
tact them, will accompany letters. If potential participants
do not return the form, they will be contacted by tele-
phone by practice staff, practice based Research Network
Clinical Studies Officers or service administrators to check
they have received the letter and asking them if they wish
to participate in the COBRA trial. Potential participants
identified by either written or telephone routes will be
initially telephone screened by researchers to confirm the
presence of depressive symptoms, and to explain the trial
fully. If positive on the screen, potentially eligible partici-
pants will be interviewed face-to-face by researchers to con-
firm eligibility, take consent, conduct a diagnostic interview
and collect baseline measures. Eligible, fully informed and
consenting participants will then be entered into the study
and randomisation (See Figure 1).
Trial interventions
We have specified our BA and CBT for depression inter-
vention protocols in line with (a) the original treatment
protocols [9,15,17-19,30,31] and (b) NICE recommenda-
tions [7] for duration and frequency of BA and CBT. Torecognise realities of real world clinical presentations, our
protocols will include behavioural and cognitive strategies
for managing comorbidity, particularly anxiety, where this
is present in addition to depression. Participants will
receive a maximum of 20 sessions over 16 weeks with
the option of four additional booster sessions [7].
Behavioural activation
The overall goal of BA is to re-engage participants with
stable and diverse sources of positive reinforcement from
their environment and to develop depression management
strategies for future use. Mental health workers delivering
BA will follow a revised treatment manual based on that
used in our Phase II trial [24] and previous international
studies [30], incorporating recommendations from NICE
Guidelines [7] and advice from our international collabo-
rators, Martell and Dimidjan. Sessions will be face-to-face,
of 1-hour duration, with the option of being conducted up
to twice weekly over the first 2 months and weekly there-
after. They will consist of a structured programme increas-
ing contact with potentially antidepressant environmental
reinforcers through scheduling and reducing the frequency
of negatively reinforced avoidant behaviours. The central
behavioural technique will be functional analysis of the par-
ticipant’s problems, based on a shared formulation drawn
from the behavioural model in the early stages of treatment,
thereafter developed with the patient throughout their
sessions. Specific BA techniques include the use of a
functional analytical approach to develop a shared un-
derstanding with patients of behaviours that interfere
with meaningful, goal-oriented behaviours and include
self-monitoring, identifying ‘depressed behaviours’, de-
veloping alternative goal-orientated behaviours and
scheduling. In addition, the role of avoidance and ru-
mination will be addressed through functional analysis
and alternative response development incorporating
recent trial evidence [32].
Workers will be selected from NHS band 5 mental
health workers such as mental health nurses and para-
professional Psychological Wellbeing Practitioners [33],
and will receive 5 days training in BA. In line with the
programme developed and tested in our Phase II trial
[24], training will focus upon the rationale and skills
required to deliver the BA protocol for depression and
include sections on behavioural learning theory and its
application to depression, developing individualised
BA formulations and specific techniques used in sessions.
Training will be a mix of presentation and role-play
with repeated practise and feedback. Workers will be
competency-assessed at the end of training using standar-
dised marking criteria consistent with the BA protocol
and further training given if competency is not demon-
strated in practical clinical exercises. BA workers will re-
ceive subsequent 1-hour clinical supervision fortnightly
Assessed for eligibility (n =700)
Excluded (n=260)
Not meeting inclusion criteria 
Analysed (n=220) with imputation of missing data 
Behavioural Activation (n=220)
Allocation
Analysis
Follow-Up at 6, 12 and 18 
months
Randomized (n=440)
Enrollment
Analysed (n=220) with imputation of missing data 
Lost to follow-up or did not receive 
intervention (max n=37)
Lost to follow-up or did not receive
intervention (max n=37)
Identified from case note screening 
(n=5,300)
Excluded by GP (n=1,900)
Invited to participate (n=3,400)
Cognitive Behaviour Therapy (n=220)
Figure 1 Consort diagram describing flow of patients through study. GP, general practitioner.
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team, clinically qualified in BA.
Cognitive behaviour therapy
The overall goal of CBT is to alter the symptomatic ex-
pression of depression and reduce risk for subsequent
episodes by correcting the negative beliefs, maladaptive
information processing and behavioural patterns pre-
sumed to underlie the depression. Therapists deliver-
ing CBT will follow a treatment protocol based on the
standard manuals published by Beck and colleagues
[19,31], the manual used in our recent trial [34] and
additional advice and training resources from our US
collaborator, Steven Hollon. Sessions will be face-to-face,
of 1-hour duration, with the option of being conducted
up to twice weekly over the first 2 months and weekly
thereafter. They will consist of a structured, collabora-
tive programme. Treatment begins with agreeing a
problem list and goals for therapy, patients learning
the CBT model, behavioural change techniques, and
moves on to identifying and modifying negative automatic
thoughts, maladaptive beliefs and, if indicated, underlying
core beliefs. In later sessions, learning is translated to
anticipating and practicing the management of stressors
that could provoke relapse in the future. Specific CBT
techniques include scheduling activity and mastery be-
haviours, the use of thought records and modifying
maladaptive beliefs and rumination content. The be-
havioural elements in CBT focus on increasing activitywith practical behavioural experiments to test specific
cognitive beliefs. CBT will not take the contextual,
functional analytical approach of the BA trial arm.
CBT will be delivered by senior mental health workers
with a specialist postgraduate diploma in ‘high-intensity’
CBT from an accredited University course. These workers
are employed at NHS band 7. They will also receive a
5-day orientation training to the specific CBT protocol
[19,31], including its adaptation for co-morbidities,
cognitive theory of depression, developing individualised
cognitive formulations and specific techniques used in
sessions. Therapists will be competency assessed at the
end of training using standardised marking criteria
consistent with the CBT protocol and further training
given if competency is not demonstrated. CBT thera-
pists will receive subsequent 1-hour clinical supervi-
sion fortnightly from established supervisors in the
three sites with advice from other members of the trial
team, clinically qualified in CBT.
Intervention fidelity
We will assess the quality of and adherence to BA and
CBT clinical protocols using audiotapes of therapy
sessions. A random sample of tapes, stratified by ther-
apist, therapy session and intervention will be sent to
independent experts in both treatments for compe-
tence rating using the Cognitive Therapy Scale - Revised
[35] for CBT and the Quality of Behavioral Activation
Scale [36] for BA.
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We will conduct follow-up assessments at 6, 12, and 18
months post-baseline assessment. Our primary outcome
will be self-reported depression severity and symptom-
atology as measured by the PHQ-9 [29] at 12 months.
The PHQ-9 is a nine-item questionnaire that records the
core symptoms of depression with established excellent
specificity and sensitivity characteristics in a UK popula-
tion [37]. Our secondary outcomes will be DSM Major
Depressive Disorder status and number of depression free
days between follow-ups, assessed by standard clinical
interview (SCID) [28], anxiety assessed by the Generalised
Anxiety Disorder-7 [38], and health-related quality of life
(Short-Form Health Survey-36) [39].
Economic data
We will calculate QALYs using the EuroQol-5D (EQ-5D)-
3 L measure of health-related quality of life [40]. The
EQ-5D consists of five dimensions in the domains of mobil-
ity, self-care, usual activities, pain/discomfort and anxiety/
depression, each scored on three levels (no problems, some
problems or extreme problems) and classifies individuals
into one of 243 health states. Health states are converted
into a single summary index by applying weights to each
level in each dimension derived from the valuation of
EQ-5D health states in adult general population samples
[41]. We will collect participants’ use of BA and CBT from
clinical records, with information on additional resources
involved (for example, training, preparation, supervision
and so forth) collected directly from therapists. We will
measure all other health and social care services used, in-
cluding medication prescription and use, and productivity
losses using the Adult Service Use Schedule, designed on
the basis of previous evidence of service use in depressed
populations [42]. We will also measure productivity losses
using the absenteeism and presenteeism questions of the
World Health Organization’s Heath and Work Performance
Questionnaire [43]. We will calculate intervention costs
using a standard micro-costing (bottom-up) approach [44],
which will be based on therapist salaries plus employers
costs (national insurance and superannuation contributions)
plus appropriate capital, administrative and managerial
overheads. We will take costs for NHS hospital contacts
from NHS reference costs and apply nationally applicable
unit costs to all community health and social care contacts
[45]. We will take the cost of medications from the British
National Formulary [46].
Process data
In addition to information on age of depression onset and
number of previous episodes collected using the SCID [28],
we will also collect data on changes in specific behaviour
(Behavioural Activation for Depression Scale) [47], changes
in beliefs (Dysfunctional Attitude Scale) [48], ruminativeresponse style (Ruminative Response Scale of the Response
Styles Questionnaire) [49], hedonic tone (Snaith-Hamilton
Pleasure Scale) [50], acceptability of BA and CBT for
participants and clinicians (assessed with qualitative
process studies), and per-protocol (PP) treatment ad-
herence (from therapist case records). We will collect
qualitative data via semi-structured interviews and written
responses to access participants’ accounts of the mech-
anisms and impacts of treatment. At the end of treat-
ment, participants will write short accounts of their
experiences of, and perceived impacts of, treatment in
response to open-ended questions. Additionally, we
will undertake semi-structured interviews designed to
obtain a more in-depth understanding of the on-going
mechanisms and impact of treatment with purposively
sampled participants and therapists building on the
analysis of the written accounts. Interviews will focus
on the participants’ views of the role of cognitive and
behavioural change strategies and broader impacts of
treatment in participants’ lives. Integration with the
quantitative process data will enhance understanding
of change mechanisms that can improve these treatments’
potential efficacy [51,52].
Sample size calculation
We have estimated the non-inferiority margin for the
primary outcome (PHQ 9) using two potential approaches
with reference to: (1) the effect size of historical trials
comparing BA versus control; and (2) the published
minimum clinically important difference for the primary
outcome (PHQ-9) of 2.59 to 5.00 [53]. Based on our
meta-analysis, BA was superior to control in depression
score by a mean of 0.7 SD units (95% CI: 0.39 to 1.00) or
3.8 (2.1 to 5.4) on PHQ-9 score units (assuming an SD of
5.4 from Lowe and colleagues [53]). It has been proposed
that non-inferiority margins be taken as ~0.5 ×mean con-
trol effect size (that is, 0.5 × 3.8 = 1.90) or as the lower
95% limit of the control effect size (that is, 2.1) [54,55]. To
ensure the adequacy of this trial to test non-inferiority
between BA and CBT, we therefore examined a number
of potential scenarios taking in account the potential
uncertainty in the non-inferiority margin for the primary
outcome (Table 1).
We have selected a conservative non-inferiority mar-
gin of 1.90 and power of 90%. As a consequence, we will
need to recruit a total of 440 participants to detect a
between-group non-inferiority margin of 1.90 in PHQ-9
at 1-sided 2.5% alpha, allowing for 20% attrition caused by
drop outs and protocol violators. Furthermore, although
previous trials of CBT have shown little or no effects of
clustering in outcome by therapists, even when delivering
group CBT [56,57], if we were to assume a small therapist
clustering effect (that is, intra-cluster correlation coefficient
of 0.01) this sample size would still have 80% power for
Table 1 Sample size calculation
Approach MICD Power Attrition
rate
Sample size
per group*
50% BA-control effect size 1.90 90% 20% 220
50% BA-control effect size 1.90 80% 20% 160
LCI BA-control effect size 2.10 90% 20% 180
LCI BA-control effect size 2.10 80% 20% 135
Lower MCID 2.59 90% 20% 120
Lower MCID 2.59 80% 20% 90
*Calculated assuming Patient Health Questionnaire 9 SD of 5.4 [33] and
1-sided 2.5% alpha using NQuery v7.0 MTE0-6, NQuery Statistical Solutions,
4500 Airport Business Park, Cork, Ireland. BA, behavioural activation; LCI, lowest
confidence interval; MCID, minimum clinically important difference.
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2.5% alpha, allowing for 20% attrition.
Our sample size is inflated by 20% for participant drop
out to take account of those that exit the trial and refuse
follow-up assessment, although our experience running
large primary care trials of depression treatment is that
attrition rates will be less than this. Therefore, we intend
to recruit 440 participants to the trial, 220 per arm.
Data analysis
All analyses will be carried out using an a priori statistical
analysis plan prepared in the first 6 months of the trial and
agreed with the Trial Management Group, Trial Steering
Committee (TSC) and the Data Monitoring Committee.
Equivalence of baseline characteristics and outcomes
in the two groups will be assessed descriptively. Since
differences between randomised groups at baseline could
have occurred by chance, no formal significance testing will
be conducted. We will also undertake a descriptive analysis
of the baseline patient characteristics according to the
recruitment method (IAPT versus case note review).
We will analyse and report primary and secondary
outcomes in accordance with reporting guidelines for
non-inferiority and equivalence trials [27]. In a super-
iority trial, ITT analysis is conventionally used as the
most conservative approach to minimise the possibility of a
type I error - that is, falsely concluding that one treatment
is superior to another. ITT includes data in the primary
analysis from participants who drop out or violate the
protocol to ensure differences between treatments under
test are not falsely inflated and ensuring the most rigorous
conditions apply before rejection of the null hypothesis
(that is, treatment A is not superior to treatment B).
However, in non-equivalence trials the null hypothesis
is the opposite, and states that the experimental treat-
ment is inferior to the reference treatment. CONSORT
guidelines for such trials [27] recommend analyses to
maximise the chances of finding a difference between
treatments ensuring stringent conditions apply before
rejection of the specific non-inferiority null hypothesis.Paradoxically, because conventional ITT analysis tends
to bias towards not finding a difference, adopting an ITT
approach could make the null-hypothesis easier to reject
in non-inferiority trials by a “blurring of the difference
between the treatment groups [which] increases the
chance of finding equivalence” [58] - that is, a false non-
inferiority result (type I error). Whilst the CONSORT
guidelines recommend a PP approach (that is, analysis
according to actual treatment received) as the conservative
non-inferiority analysis option, given the potential biases
of both PP and ITT analyses, we agree with the European
Agency for the Evaluation of Medicinal Products that
security of inference depends on both PP and ITTanalyses
demonstrating non-inferiority of the primary outcome
[55]. We will, therefore, check for non-inferiority in PP
and ITT populations, conducting sensitivity analyses on
the primary outcome for PP and imputed ITT populations
to check the security of inference of non-inferiority. We will
also conduct sensitivity analyses using different definitions
of PP adherence. We will include varying proportions of
PP participants in these sensitivity analyses populations,
depending on how much of each therapy they have re-
ceived, ranging from 40 to 100% of planned therapy
sessions. If non-inferiority is consistently shown by
these analyses, we will proceed to assess superiority of
CBT versus BA - that is, the CI lower bound lies above 0.
If conclusions are inconsistent across analyses we will
revert back to primacy of the PP analysis to confirm or
refute the non-inferiority hypothesis.
The primary analysis will compare primary and secondary
outcomes between BA and CBT groups at 12 months after
randomisation adjusting for baseline outcome values and
stratification variables (symptom severity, site, antidepres-
sant use) and fitting therapist as a random effects variable.
The one-sided 97.5% CI for the between-group difference
will be estimated and non-inferiority of BA compared to
CBT will be accepted (in a 0.025 level test) if the lower
bound of the 97.5% CI lies within the non-inferiority
margin of −1.90 in PHQ-9 score. If non-inferiority is
shown, we will then test for superiority of CBT over
BA (that is, lower bound of the 97.5% CI lies above 0).
We will check for non-equivalence at all follow-up
points using the same approach. Secondary analyses will
be undertaken to compare groups at follow-up across 6, 12,
and 18 months using a repeated-measures approach. The
analysis will be extended to fit interaction terms to explore
possible differences in treatment effect in baseline symptom
severity and antidepressant usage. Sensitivity analysis,
making different assumptions about the imputation
model used, will be conducted for both primary and
secondary analyses to assess the likely impact of miss-
ing data. Models will be fitted using generalized linear
mixed models and undertaken in STATA v.11, STATA,
StataCorp LP, 4905 Lakeway Drive, College Station, Texas
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portions of participants meeting criteria for “recovery”
(proportions of participants with PHQ-9 scores ≤9)
and “response” (50% reduction in scores from baseline)
on the PHQ-9.
Economic analysis
We will compare the costs and cost-effectiveness of BA
and CBT at the final 18-month follow-up to capture the
economic impact of events such as relapse, although we
will conduct an initial preliminary analysis at 12 months
to support the primary clinical analyses. Our primary ana-
lysis will take the NHS/personal social services perspective
preferred by NICE [59]. The impact of productivity losses
as a result of time off work, known to be a substantial
cost in depression [60], will be explored in sensitivity
analysis. In addition, narrower cost perspectives will be
tested (for example, an intervention perspective and a
mental health care perspective), to ensure that the
NHS/personal social services perspective has not cap-
tured irrelevant costs that may hide the true impact of
BA and CBT on service use.
Costs will be disaggregated to ensure the costs of
each intervention and the costs to the different sectors
(health, social care, employment) are clear. Although the
distribution of costs is commonly skewed in populations
of this kind, our analyses will compare mean costs using
standard parametric t-tests with covariates for pre-specified
baseline stratification factors plus baseline costs. We
will confirm the robustness of the parametric tests
using bias-corrected, non-parametric bootstrapping
[61,62]. Whilst studies designed to test equivalence of
effects are considered to be a legitimate situation in
which a cost-minimisation analysis (where costs alone
are compared given equal outcomes) may be appropri-
ate [62], the same may not be true for non-inferiority
designs. Even in situations where equivalence or non-
inferiority are demonstrated, exploration of the joint
distribution of costs and effects in a cost-effectiveness
analysis is recommended to represent uncertainty [62]
and to help interpret the economic results [58]. For
these reasons, we will undertake a cost-effectiveness
analysis irrespective of whether or not non-inferiority
in the primary clinical outcome is demonstrated.
We will assess cost-effectiveness in terms of QALYs
using the net benefit approach [63] with reference to
Bosmans’ methods [58] for economic evaluations alongside
equivalence or non-inferiority trials. Uncertainty around
the cost and effectiveness estimates will be represented
by cost-effectiveness acceptability curves [64,65]. We
will generate a joint distribution of incremental mean costs
and effects for the two therapies using non-parametric
bootstrapping to explore the probability that each of
the treatments is the optimal choice, subject to a rangeof possible maximum values (ceiling ratio) that a decision-
maker might be willing to pay for an additional QALY
gained. We will present cost-effectiveness acceptability
curves by plotting these probabilities for a range of possible
values of the ceiling ratio [66], a recommended decision-
making approach to dealing with the uncertainty that exists
around the estimates of expected costs and expected effects
associated with the interventions under investigation and
uncertainty regarding the maximum cost-effectiveness ratio
that a decision-maker would consider acceptable [66,67].
Process data analysis
Based on recent reviews [68], exploratory analyses will
examine baseline variables that might moderate outcome at
multiple time points (6, 12 and 18 months) across the two
treatments (including depression severity, age of depression
onset, number of previous episodes, and baseline levels of
cognitive and behavioural dysfunction) using the approach
set out by Kraemer and colleagues [51]. Although the
power to detect moderate subgroup interactions will be
low, we are primarily interested in exploring the possibility
of large interactions that could inform subsequent clinical
decision-making regarding treatment allocation.
Mediational analyses will investigate the hypothesised
mechanisms of change (for BA: changes in specific be-
haviour such as reduced avoidance and rumination,
learned capacity to apply behavioural principles to
modify the environment; for CBT: changes in beliefs
and underlying information processing style) pre-treatment
to mid-treatment, and mid-treatment to post-treatment
across the trial arms using approaches to testing mediation
that allow multiple mediators in one model [51]. We will
also analyse audio recordings of BA and CBT sessions to
assess changes in putative mediators amongst patient and
therapist within-session behaviour [52]. The effects of
the mediators on outcome at 12 and 18 months will be
modelled. This approach to examining mediation ensures
that changes in putative mediators temporally precede
changes in the primary outcome and allow baseline-to-
post-treatment change in symptoms to be statistically
controlled, necessary to rule out reverse causality. Ana-
lyses will include multivariate growth models including
autoregressive and lagged terms, as well as recent develop-
ments in mediator analysis that use instrumental variables
to account for the effect of unobserved confounding on
mediators - we will follow precedent in using treatment
allocation and its interaction with baseline measures as in-
strumental variables [69].
Qualitative data analysis
Qualitative data will be analysed using a framework analysis
[70] combining inductive and deductive approaches. The-
matic frameworks will be developed from a combination
of interview topics and data collected from participants to
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will be examined thematically across the whole dataset as
well as in the context of each interview, using a constant
comparative analysis approach [71]. Data will be indexed,
rearranged and mapped onto the identified themes and
subthemes and interpreted and reanalyzed within the the-
matic framework to distil, interpret and structure compo-
nent statements, the original transcripts being frequently
revisited to clarify contextual meaning.
Ethical issues
We will conduct the trial is such a way as to protect the
human rights and dignity of the participants as reflected
in the Helsinki Declaration [72]. Participants will not re-
ceive any financial inducement to participate. The study
has received Multi-Centre Research Ethics Committee
approval from the South West Research Ethics Committee
in the UK. Local Research Ethics Committee and NHS
Research and Development approvals have also been given
for each recruitment site. To conform to data protection
and freedom of information acts, all data will be stored se-
curely and anonymised wherever possible. No published
material will contain patient identifiable information.
Obtaining informed consent from participants
We will determine informed consent by a two-phase con-
sent process. Participants will receive a study information
sheet in the post and a form seeking their permission to be
contacted by a member of the research team, not at this
stage to give consent to trial participation. The information
leaflets will be produced using the current guidelines for re-
searchers on writing information sheets and consent forms,
posted on the UK ethics website (http://www.nres.nhs.uk/
applications/guidance/consent-guidance-and-forms/) and
informed by our consumer/lived experience user repre-
sentatives. Participants who wish to partake in the trial
will return their initial consent to be contacted form to
the site research team. Full informed consent will only
be obtained through an interview by a researcher where
the information sheet is fully explained and where the
opportunity to ask questions is given. The opportunity
to withdraw from the trial will be fully explained. Re-
searchers seeking consent will be fully trained and su-
pervised by the chief investigator and site leads.
Communication and recording systems will be set up
to enable the trial team to monitor and act on partici-
pants’ wishes to withdraw from the trial.
Anticipated risks and benefits
All participants will receive usual GP care, and therefore
no treatment will be withheld to participants in this trial.
Both arms are active psychological treatments with
previously demonstrated efficacy and no known iatro-
genic effects. This trial may in fact benefit individualparticipants, since CBT is not generally available for
the majority of people with depression. By participating
in this trial, participants will also receive an intensive
level of monitoring such that any participants worsening
or at suicidal risk will be identified and directed to ap-
propriate care.
Informing participants of anticipated risks and benefits
Participant information leaflets will provide potential
participants with information about the possible bene-
fits and known risks of taking part in the trial. Partici-
pants will be given the opportunity to discuss this issue
with their GP or the trial manager prior to consenting.
The trial manager will inform the participant if new in-
formation comes to light that may affect the partici-
pant’s willingness to participate in the trial.
Suicide and suicide attempts
Inherent in the nature of the population under scrutiny
is the risk of suicide. We will follow good clinical prac-
tice in monitoring for suicide risk during all research
and clinical encounters with trial participants developed
for our previous trials, for example [34,73]. Where any
risk to participants due to expressed thoughts of suicide
is encountered, we will report these directly to the GP
(with the participant’s expressed permission), or if an
acute risk is present we will seek advice from the GP
immediately and follow locally established suicide risk
management plans. Systems will be put into place to
ensure that the chief investigator, trial manager and re-
searchers will be informed should there be any risks to
the participants’ safety.
Patient and public involvement
The COBRA team work closely with UK mental health
consumer organisations including RETHINK and De-
pression Alliance. The chief executive of Depression
Alliance (O’Neill) is a co-investigator on this trial and
has advised the team throughout. All sites have excellent
local patient and public involvement (PPI) mechanisms
led from the Exeter Mood Disorders Centre via our
‘Lived Experience Group’ - 20 people with personal ex-
perience of depression and its treatment. O’Neill and
at least one member of the Lived Experience Group will at-
tend all Trial Management Group meetings. Selection and
writing of participant materials (trial information leaflets
and consent forms; clinical materials; training materials)
will be edited by this group. We will follow national good
practice guidance for researchers on public involvement in
research and the paying of PPI representatives actively
involved in research at www.invo.org.uk. We will also
work with our PPI representatives to ensure that our
dissemination strategies are inclusive and accessible to
other people who use services.
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Committee
A TSC will be set up and include an independent chair,
an academic GP and at least two other independent
members, along with the lead investigator and some
other study collaborators. The TSC will meet at least
once a year. A Data Monitoring and Ethics Committee
(DMEC) committee will be set up and comprise an in-
dependent mental health statistician and clinician. The
role of the DMEC is to review serious adverse events
thought to be treatment related and look at outcome
data regularly during data collection.
Forecast execution dates
The preparatory period started in March 2012. Recruitment
is running from September 2012 to June 2014. Follow
up will last 18 months, at 6 (T1), 12 months (T2) and
18 (T3) months after randomisation. Data analysis and
reporting will take another 6 months. The entire study
period will last for 48 months.
Discussion
This trial is designed to test the clinical and economic
benefits of BA compared to the current gold standard
psychological treatment of depression, CBT. Our non-
inferiority design and analytical strategy will determine
if BA is substantially inferior to this standard.
Trial status
Recruitment commenced in September 2012 and is
ongoing.
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